Publications

Efficacy and safety of risankizumab for active psoriatic arthritis: 100-week results from the Phase 3 KEEPsAKE1 randomized clinical trial

Rheumatol Ther 2024 doi: 10.1007/s40744-024-00654-5 Epub ahead of print

Kristensen LE,

Keiserman M,

Papp K,

McCasland L,

White D,

Carter K,

Lippe R,

Photowala H,

Drogaris L,

Soliman AM,

Chen M,

Padilla B,

Behrens F

Risankizumab therapy was associated with significant and sustained improvement in multiple disease domains from Week 52 through Week 100, compared with placebo. Kristensen et al. investigated the safety, efficacy and tolerability of 100-week risankizumab therapy in PsA patients with previous inadequate response to ≥1 csDMARD, using data from KEEPsAKE 1 trial.

Keywords:

• Efficacy,
• Risankizumab,
• Safety,
• IL-23,
• LTE

MACE et TEV dans les programmes d'essais cliniques de l'Upadacitinib dans la polyarthrite rhumatoïde, le rhumatisme psoriasique et la spondylarthrite ankylosante

RMD Open 2023; 9(4):e003392 doi 10.1136/rmdopen-2023-003392

Charles-Schoeman C,

Choy E,

McInnes IB,

Mysler E,

Nash P,

Yamaoka K,

Lippe R,

Khan N,

Shmagel AK,

Palac H,

Suboticki J,

Curtis JR

Rates of MACE and VTE events in patients with RA or PsA treated are consistent across 15 mg and 30 mg doses of upadacitinib, and comparable with active comparators adalimumab and MTX. Several risk factors were also identified for MACE and VTE events in patients with RA.

Keywords:

• Baricitinib,
• Cardiovascular,
• JAK,
• MTX,
• Outcomes,
• Phase 3,
• Remission,
• Safety,
• Tofacitinib,
• Updacitinib

Propriétés différentielles des inhibiteurs de Janus Kinase dans le traitement des maladies inflammatoires à médiation immunitaire

Rheumatology (Oxford) 2023;63(2):298–308 doi 10.1093/rheumatology/kead448

Taylor PC,

Choy E,

Baraliakos X,

Szekanecz Z,

Xavier RM,

Isaacs JD,

Strengholt S,

Parmentier JM,

Lippe R,

Tanaka Y

JAKis differ in structure, which affects their inhibitory concentration for different JAKs.

This review by Taylor, et al. compares the pharmacological profiles of JAKis, including abrocitinib, baricitinib, filgotinib, peficitinib, tofacitinib, and upadacitinib.

Keywords:

• JAK,
• Basic Science,
• MOA

Efficacité et sécurité de l'upadacitinib chez les patients atteints de rhumatisme psoriasique : résultats à deux ans de l'étude de phase 3 SELECT-PsA 1

Rheumatol Ther. 2022 Oct 15:1–18 doi: 10.1007/s40744-022-00499-w

McInnes IB,

Kato K,

Magrey M,

Merola JF,

Kishimoto M,

Haaland D,

Chen L,

Duan Y,

Liu J,

Lippe R,

Wung P

Results from the long-term extension of SELECT-PsA 1 show efficacy responses similar or greater with upadacitinib, 15 or 30mg, versus adalimumab through 104 weeks.

Keywords:

• JAK,
• Updacitinib,
• Phase 3,
• LTE

Profil d'innocuité de l'upadacitinib jusqu'à 3 ans dans le rhumatisme psoriasique : une analyse intégrée de deux essais pivots de phase 3

Rheumatol Ther. 2022 doi: 10.1007/s40744-021-00410-z

Burmester G,

Winthrop K,

Blanco R,

Nash P,

Goupille P,

Azevedo V,

Salvarani C,

Rubbert-Roth A,

Lesser E,

Lippe R,

Lertratanakul A,

Mccaskill RM,

Liu J,

Ruderman EM

Upadacitinib 15 mg once daily demonstrated a similar safety profile to adalimumab 40 mg every other week, except for higher rates of HZ and opportunistic infections with upadacitinib treatment in patients treated for PsA

Keywords:

• JAK,
• Updacitinib,
• Phase 3,
• Safety

A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition

Rheumatology (Oxford). 2021. Epub ahead of print. doi: 10.1093/rheumatology/keab740.

McInnes IB,

Szekanecz Z,

McGonagle D,

Maksymowych WP,

Pfeil A,

Lippe R,

Song IH,

Lertratanakul A,

Sornasse T,

Biljan A,

Deodhar A

JAK inhibitors are likely to become an important part of the overall treatment paradigm for spondyloarthritis (SpA).Although not fully understood, the pathogenesis of SpA is complex and thought to involve both environmental and genetic factors that together elicit a chronic inflammatory response involving the innate and adaptive immune systems. Several different cytokines, TNF, IL-17A, IL-12/23 and IL-23, which are directly/indirectly affected by JAK molecules, are involved in the pathogenesis o...

Keywords:

• JAK,
• Basic Science,
• Review

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study

RMD Open. 2021;7(3):e001838

McInnes IB,

Kato K,

Magrey M,

Merola JF,

Kishimoto M,

Pacheco-Tena C,

Haaland D,

Chen L,

Duan Y,

Zueger P,

Liu J,

Lippe R,

Pangan AL,

Behrens F

Analysis of data over 56 weeks shows that efficacy responses are maintained with upadacitinib 15 mg and 30 mg.Following the publication of 12-week data from the Phase III, randomised double-blind, SELECT-PsA 1 study, earlier this year, McInnes, et al. now report the 56-week efficacy and safety data of upadacitinib 15 mg and 30 mg in patients with PsA and an inadequate response to non-biological therapyEfficacy responses and inhibition of radiographic progression were maintained with upadacitinib...

Keywords:

• JAK,
• Updacitinib,
• Phase 3

Efficacité de la Monothérapie avec des Biomédicaments et des Inhibiteurs de JAK pour le Traitement de la Polyarthrite Rhumatoïde : Analyse Complète

ADV Ther 2018; 35(10):1525–63 DOI: 10.1007/s12325-018-0757-2

Emery P,

Pope JE,

Kruger K,

Lippe R,

DeMasi R,

Lula S,

Kola B

The b/tsDMARDs evaluated in this systematic literature review (SLR) were shown to be efficacious as monotherapies, although combination therapies usually achieved better treatment outcomes.Current treatment guidelines recommend combining b/tsDMARDs with MTX in the treatment of RA; however, up to a third of patients are treated with monotherapy. While previous SLRs1–3 have compared the efficacy of b/tsDMARD mono- versus MTX combination therapy they covered a limited number of randomised controlle...

Keywords:

• JAK,
• Review